E-drug: Cerezyme (cont'd)
---------------------------------------------------------------------
[Please 'repair' long url's. HH]
In the UK, the seller of Cerezyme was found guilty of excessive
pricing and faced a large fine. In South Africa, the Competition
Commission found GSK and BI guilty of excessive pricing, and also
asked for a fine and a compulsory license of the patents on several
ARV drugs. We worked for the RSA CC on the GSK/BI case, and
would be happy to work with you on the problem in Kuwait.
James Love <james.love@cptech.org>
James Love, Director, Consumer Project on Technology
http://www.cptech.org, mailto:james.love@cptech.org
tel. +1.202.387.8030, mobile +1.202.361.3040
Documents in UK case
http://www.oft.gov.uk/business/competition+act/decisions/genzyme.htm
http://www.oft.gov.uk/news/press+releases/2003/pn+31-03.htm
http://www.oft.gov.uk/nr/rdonlyres/ef2d7koxitqjbe3rgc2cmchttqhkhobh
h4esdv2l36s4w7zc66nioqbybe2zq4dpcz2n3uofklh4lotsim7ifh7r37f/ge
nzyme.pdf
http://www.oft.gov.uk/news/press+releases/2002/pn+46-02+oft+propo
ses+to+find+genzyme+pricing+policy+breaches+competition+law.htm
http://www.oft.gov.uk/news/press+releases/2003/pn+102-03.htm
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug